Research on Previously Ethically Approved Samples in Bladder Cancer
Research type
Research Study
Full title
Research Expansion on Previously Ethically Approved Trial Samples in Bladder Cancer (REPEATS BC)
IRAS ID
323980
Contact name
Anna Wilkins
Contact email
Sponsor organisation
Institute of Cancer Research
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Bladder cancer is the 11th most common cancer in the UK, but survival rates have not significantly improved over the past few decades. Whilst several treatments are approved for treatment of bladder cancer, including immunotherapy, not all patients demonstrate good response and determinants of response are incompletely understood, including immune-related parameters. Comprehensive profiling of potential determinants and markers of response to therapy requires a multifaceted approach using techniques such as gene expression profiling, whole exome sequencing, TCR sequencing, multiplex immunofluorescence, flow cytometry and cytokine profiling. This study aims to assess the feasibility of obtaining these multiple different data sets from samples collected in previously ethically approved studies. Once feasibility is determined, the data collected will be related to outcomes data from the original trials for investigative work into correlations of paramters with response to treatment. Ultimately this study may lead to refinements of techniques for use in clinical practice to aid decision making.
REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
23/NE/0212
Date of REC Opinion
24 Nov 2023
REC opinion
Further Information Favourable Opinion